Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

07-04-2020 | Systemic lupus erythematosus | Infographic | Image

The TULIP-1 and TULIP-2 trials

Primary and key secondary outcome results from the TULIP-1 and TULIP-2 trials of anifrolumab.

Figure: Primary and key secondary outcome results for anifrolumab 300 mg every 4 weeks versus placebo in TULIP-1 and TULIP-2 (prespecified analysis). The key secondary outcomes were adjusted for multiple comparisons; results given with rounding as per published papers. *Statistically significant results (p≤0.05) versus placebo; †patients classified as having high interferon gene signature expression relative to healthy controls; ‡sustained from week 40, in patients taking at least 10 mg/day of prednisone or equivalent at baseline; §in patients with CLASI activity score of at least 10 at baseline.

print
PRINT

More on this topic

07-04-2020 | Systemic lupus erythematosus | Feature | Article

In pursuit of new lupus therapies: The importance of trial endpoints
Image Credits